Biollaz J, Munafo A
Département de médecine interne, Centre hospitalier universitaire vaudois, Lausanne.
Schweiz Med Wochenschr. 1988 Apr 30;118(17):616-20.
Vasodilators currently prescribed in the treatment of congestive heart failure represent a wide class of drugs. In acute heart failure, the therapeutic choice should be based on considerations about the mechanisms of drug action as well as the site of action on the vascular bed, together with the patient's hemodynamic and clinical characteristics. For medium-to long-term treatment the choice should be oriented towards drugs which do not activate compensatory or feedback regulation mechanisms. Use of therapeutic agents such as inhibitors of the angiotensin converting enzyme will avoid the development of physiological tolerance.
目前用于治疗充血性心力衰竭的血管扩张剂种类繁多。在急性心力衰竭中，治疗选择应基于对药物作用机制、在血管床的作用部位的考虑，以及患者的血流动力学和临床特征。对于中长期治疗，选择应倾向于不激活代偿或反馈调节机制的药物。使用诸如血管紧张素转换酶抑制剂等治疗药物将避免生理耐受性的产生。
